Safety and efficacy of tofacitinib for immune skin conditions in Down syndrome
This study is designed to determine whether tofacitinib is a safe and effective treatment for immune skin conditions in adults with Down syndrome, and to further our understanding of the immune system in Down syndrome. This is a single arm, open-label study. All participants will receive tofacitinib. Tofacitinib is an FDA-approved drug currently used to treat arthritis and ulcerative colitis. Participants must attend eight study visits at the University of Colorado Anschutz Medical Campus during the 18-week trial and have a study partner available to attend the visits with them. A blood draw for safety monitoring is required at each visit. Participants will be given tofacitinib at no cost for the duration of the study.
MoreChild to Adult
Adolescents and adults with Down syndrome between the ages of 12 and 50 years who have at least one active skin condition such as: - Alopecia areata affecting at least 25% of the scalp - Moderate-to-severe atopic dermatitis or eczema - Moderate-to-severe hidradenitis suppurativa or boils - Moderate-to-severe psoriasis - Moderate-to-severe vitiligo
Other eligibility requirements exist. Only study personnel can determine eligibility.
Treatment
Childrens Hospital Colorado
Outpatient CTRC
University of Colorado Hospital
Joaquin Espinosa, PhD
Protocol Number: 19-1362
More information available at ClinicalTrials.gov: NCT04246372
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers